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Tumour targeting by means of monoclonal antibodies (mAbs)
directly conjugated to isotope or drugs has been extensively inves-
tigated for imaging and therapy with relatively disappointing
results.
Alternative methods for tumour targeting include the indirect
(two-step) delivery system where a reagent can interact specifi-
cally with both the target and effector compound. This system
involves the use of bi-specific antibodies (BiAbs) which have two
different specific antigen binding sites, one for the tumour-
associated antigen and one for the effector compound (e.g. the
CD3 receptor of T-cells or an isotope such as 111In). BiAbs that
cross-link the T-cell-associated TcR/CD3 receptor with the tumour
cells, promote an activation signal that mediates cytotoxicity
against the target cell in an MHC-independent way, regardless of
the T-cell specificity (Perez et al, 1985; Staerz et al, 1985). In very
few studies such as a lymphoma model in mice (Demanet et al,
1992) and a small clinical trial of intracavitary administration in
glioma patients (Nitta et al, 1990) cure of established tumours was
achieved. Furthermore, BiAb application in vivo has not been
shown to result in specific localization of BiAbs and T-cells in
solid tumours.
A more sophisticated version of the indirect approach for
tumour targeting is offered by the ‘universal bispecific antibody
approach’ (Gilliland et al, 1988). In this system, specific anti-
tumour mAbs are first localized at the target site. The universal
BiAb, an anti-CD3 ´ anti-Ig BiAb, is then administered. The anti-
Ig arm binds to the specific anti-tumour mAbs and the anti-CD3
arm cross-links the CD3 receptor to activate cytotoxic T-cells,
leading to the destruction of tumour cells. A similar approach has
been used to target recombinant Ab fragments (George et al,
1994). This approach has the advantage of being less expensive
since the ‘universal BiAb’ can be used to redirect effector cells
against a variety of tumours, and offers the opportunity of
targeting more than one tumour associated antigen at the same
time (George et al, 1994).
The indirect approach has also been modified for in vivo tumour
imaging studies providing data on pharmacokinetics and biodistri-
bution. A first step injection of anti-tumour ´ anti-tracer BiAb is
followed by injection of the tracer compound (Le Doussal et al,
1992). The advantages of the indirect in vivo imaging compared
to the direct approach (mAb directly conjugated to tracer) include:
(i) higher tumour/tissue ratios (especially with liver, spleen and
kidneys) and (ii) faster contrast images.
An alternative approach for signal amplification in tumour
targeting is represented by the streptavidin (SA)–biotin indirect
system for tumour imaging which has resulted in the further reduc-
tion of background noise and amplification of the target bound
signal (Hnatowich et al, 1987; Paganelli et al, 1988; Kalofonos et
al, 1990; Zhu et al, 1998). The technique which exploits the high
affinity of biotin for SA, consists of an initial injection of strepta-
vidin-conjugated antibodies that are accumulated at the target
sites. After blood clearance of free SA–mAb, radiolabelled biotin
is injected that binds to the target-bound SA–mAbs while the
remaining free radiobiotin clears rapidly from the blood by
glomerular filtration. Zhu and colleagues demonstrated a 200%
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Correspondence to: GWH Stampincrease in the tumour:background ratio with the SA–biotin
approach as compared with the BiAb method (Zhu et al, 1998).
Furthermore, the latter study showed that tumour antigen expres-
sion and shedding had little effect on the isotope delivery to the
tumour. Despite the potential benefits of this approach, it has yet to
be investigated in the therapeutic context.
The aim of this study has been to develop the SA–biotin
approach to improve T-cell redirection at the tumour site for
immunotherapeutic applications. In order to achieve this we have
directly streptavidinylated an anti-tumour antibody and biotiny-
lated monovalent antibody Fab fragments (without Fc region 
to avoid T-cell activation/sequestration by cells expressing
membrane receptors for the Fc) raised against the CD3 receptor on
T-cells. In theory, tumour cells targeted by the antibody conjugated
with SA will bind the biotinylated anti-CD3 Fab causing its
aggregation (i.e. making an artificially bivalent or polyvalent
antibody construct), thus rendering it able to deliver an efficient
activation signal for the T-cells (Figure 1). We selected MUC1
mucin, a well-documented antigen of human adenocarcinomas
(Taylor et al, 1994) as the target tumour antigen.
MATERIALS AND METHODS
Target BALB/c breast cancer cell lines
Five cell lines were used in this study: the mouse 410.4 parental
cell line, three transfected clones (435DNV, 413BCR, 425CCR)
and the human MCF-7 cell line.
Tumour cell lines used as target originated from 410.4, the 4th
transplant generation (Blazar et al, 1980) of a lung metastatic
nodule (410) isolated from the 10th subcutaneous passage of an
original mammary tumour that arose spontaneously in a strain
BALB/c breeding female (Heppner et al, 1978). The 410.4 cell
line has a high malignant potential, metastasizes spontaneously
with high frequency (> 80%) to the lungs of mice injected sub-
cutaneously or intravenously, and shows lack of immunogenicity
(Miller et al, 1993). The 410.4 cell line was transfected with 3.9 kb
full-length MUC1 cDNA, kindly provided by Dr M Hollingsworth
(Batra et al, 1991), under the control of the b-actin promoter, in the
mammalian expression vector pHb-Apr-1-neo by the calcium
phosphate precipitation method (M Hudson et al, manuscript in
preparation). Transfected clones were selected in Dulbecco’s
modified Eagle’s medium containing 600 mg ml–1 G418-sulphate,
10% fetal bovine serum (FBS), 100 U ml–1 penicillin, 100 mg ml–1
streptomycin and 0.2 mg ml–1 butyl-p-hydroxybenzoate (all from
Gibco-BRL). The parental line was grown in a similar media but
without G418-sulphate.
In this study three transfected cell lines were used: the 435DNV
(G418 resistant; vector control) and the MUC1 mucin-transfected
clones 413BCR and 425CCR.
The MCF-7, a human breast adenocarcinoma cell line, isolated
from a patient’s pleural effusion (Soule et al, 1973) and previously
shown to express MUC1 mucin (Devine and McKenzie, 1992),
was used as a positive control cell line.
T-cell purification and culture of BALB/c effector T-cells
T-cells were purified from spleens of 6–10 weeks old female
BALB/c mice using a mouse T-cell purification column according
to the manufacturer’s instructions (Pierce). Samples were analysed
by flow cytometry for CD3 epitope density using the 500A2 mAb
(Havran and Allison, 1988). Preactivated cytotoxic T lymphocytes
(CTL) were generated in bulk culture using media contain-
ing RPMI-1640 (Gibco), 10% heat inactivated FBS (Life
Technologies) pre-screened to support T-cell growth, 100 U ml–1
penicillin, 100 mg ml–1 streptomycin, 2 mML -glutamine, 5 ´ 10–5 M
2-mercaptoethanol, 4 mg ml–1 Concavalin A (ConA; Sigma) and
50 U ml–1 human recombinant interleukin 2 (IL-2 endotoxin
tested; Boehringer Mannheim), and maintained in a 5% carbon
dioxide humidified incubator, at 37°C. T-cell proliferation was
tested by flow cytometry using propidium iodide for DNA staining
as previously described (Nicoletti et al, 1991).
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Figure 1 The strategy of the novel antibody approach for the redirection of
T-cells against tumour cells. MUC1 mucin-expressing tumour cells labelled
with streptavidinylated anti-MUC1 MAb (HMFG1 SA) cross-linking
biotinylated anti-CD3 Fab fragments (Fab Bio) bound on ConA/IL-2
preactivated T-cells by biotin–streptavidin bondThe two-step targeting approach
The tumour targeting step
Anti-MUC1 mucin monoclonal antibody. HMFG1, an IgG1 mAb
raised in mouse against the human MUC1 mucin was kindly
donated by the Imperial College Research Fund (ICRF; London,
UK). This antibody that recognizes the PDTR sequence of the
mucin’s tandem repeat protein backbone was previously shown to
specifically localize to malignancies expressing MUC1 mucin in
the context of imaging studies (Epenetos et al, 1982). Cell binding
studies by flow cytometry were carried out to test HMFG1 binding
to MUC1 mucin expressing cells using as second layer fluorescein
isothiocyanate (FITC)-conjugated rabbit anti-mouse serum
(Dako).
Streptavidinylation of anti-MUC1 mucin HMFG1 mAb.
Streptavidinylation of the HMFG1 IgG mAb was achieved by
three conjugation reactions described in Figure 2. In the first
reaction N-hydroxysuccinimide ester of S-acetylthioacetic acid
(SATA; Pierce) was used to introduce a free sulphydryl (-SH)
group onto HMFG1 as previously described (Duncan et al, 1983).
SATA:IgG ratios were assayed in the range of 1:1 to 20:1 and -SH
incorporation was tested using 5,5¢-dithio-bis-(2-nitrobenzoic
acid) (Pierce) as previously described (Ellman, 1959). In the
second reaction, sulphosuccinimidyl 4-[N-maleimidomethyl]
cyclohexane-1-carboxylate (S-SMCC; Pierce) was used to
introduce a maleimide group onto SA (Pierce) according to a
method previously described (Hashida et al, 1984). In the third
reaction the two conjugates were mixed together in equimolar
ratios to react by a sulphydryl-maleimide bond. Streptavidinylated
HMFG1 was separated from unreacted streptavidin and antibody
aggregates using microconcentrators of appropriate molecular
weight cut-off (Amersham). Successful HMFG1 streptavidinyla-
tion was tested by binding studies to 413BCR cells using flow
cytometry and cytospin preparations. Negative control experi-
ments included 410.4 parental cell line and 413BCR transfectant
cells incubated with cross-linking reagents, SA or anti-SA serum.
The T-cell redirection step
Anti-CD3 mAb. 1452C11, an Armenian hamster IgG mAb reacts
with the 25-kDa e chain of the T-cell receptor-associated CD3
complex and can activate primed and unprimed T-cells in vitro and
in vivo (Leo et al, 1987; Portoles et al, 1989). 1452C11 mAb can
also induce redirected lysis of Fc receptor-bearing target cells by
CTL clones (Leo et al, 1987). 1452C11 was acquired in no
azide/low endotoxin format from PharMingen UK. Fab fragments
were generated by papain digestion (Pierce) and purified from Fc
and intact IgG using standard affinity chromatography procedures
with Protein G 4FF column (Pharmacia). Non-reducing 12.5%
sodium dodecyl sulphate-polyacrylamide gel electrophoresis
(SDS-PAGE) (Laemmli et al, 1970) and staining with Coomassie
brilliant blue were carried out to monitor Fab fragmentation and
purification.
Biotinylation of anti-CD3 Fab fragments. Biotinylation of Fab
fragments was carried out using N-hydroxysuccimidoiminobiotin
hydrobromide (Pierce) at different molar ratios (Biotin/Fab
7:1–50:1) as previously described (Orr, 1981). Fab fragments were
tested for biotin content using the HABA method ([2-(4¢-hydroxy-
azobenzene) benzoic acid]; Pierce) as previously described
(Green, 1965). Biotinylated anti-CD3 Fab fragments were sepa-
rated from unreacted biotin and antibody aggregates using micro-
concentrators of appropriate molecular weight cut-off. In addition,
biotinylated Fab fragments were tested for specificity and ability
to bind SA by flow cytometry and cytospin preparations of T-cells
using as detecting reagent FITC-conjugated SA (Dako).
Testing the two-step approach
Flow cytometry
Single-cell suspension of tumour cell lines or T-cells were resus-
pended in 2% FBS/PBS. Then 106 cells were incubated with first
layer antibody (10 mg ml–1) for 30 min. Following washes in 2%
FBS/PBS to remove unbound antibody, cells were incubated with
second layer antibody (same procedure was applied for more anti-
body layers) for 20 min at 4°C in the dark, and three washes were
performed after every layer to remove unbound reagent. After a
final incubation in FITC-labelled antibody solution, cells were
washed and resuspended in 2% FBS/PBS and subsequently
analysed in a Coulter Epics XL-MCL cell sorter for fluorescence
emission at 525 ± 10 nm (Fl1). The cross-linking property of the
streptavidinylated anti-tumour mAb and biotinylated anti-CD3
Fab fragments was also tested by flow cytometry. Briefly, T-cells
were incubated initially with excess biotinylated anti-CD3 Fab
fragments then with excess streptavidinylated HMFG1 mAb
followed by rabbit anti-SA serum (Sigma) and then by FITC-
conjugated goat anti-rabbit serum (Dako) at the concentrations
indicated by the manufacturers. Negative control experiments
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Figure 2 Schematic representation of the reactions involved in the direct
streptavidinylation of HMFG1 mAb. Step 1: (a) Introduction of a -SH group,
protected from oxidation by an acetyl group, on the HMFG1 mAb by
employing SATA. (b) Deprotection of -SH group by removing the acetyl group
with hydroxylamine (NH2OH). Step 2: Addition of a maleimide group onto
streptavidin using S-SMCC. Step 3: Streptavidinylation of HMFG1 mAb by a
covalent amide-thioether bondusing first layer antibodies alone or second/third layer reagents
were included.
51Cr cytotoxicity assay
A standard 51Cr release assay was performed as previously
described (Brunner et al, 1968).
Preparation of target cells. Parental 410.4 and MUC1-trans-
fected 413BCR and 425CCR culture cells at subconfluent phase
were gently detached with versene–trypsine solution and single
cell suspended. Viability test was carried out and groups of 106
cells for each target cell line were mixed with 50 mCi of 51Cr
isotonic solution (Amersham) for 1 h at 37°C in a humidified 5%
carbon dioxide incubator. Subsequently, selected groups of each
target cell line were then added to 200 ml of medium containing 2
mg of streptavidinylated anti-MUC1 mucin antibody construct
(streptavidinylated HMFG1 IgG) and left at 4°C for 30 min.
Control groups derived from each target cell line did not receive
anti-MUC1 mucin antibody. Cells were then washed three times to
remove unbound antibody and placed in a 96-well plate at a
concentration of 5 ´ 103 cells per well. Maximum release was
determined by wells containing control groups with added deter-
gent (SDS) and represent 100% lysis of target cells. Spontaneous
release was determined by wells containing control groups with no
detergent or CTL.
Preparation of effector cells. Preactivated CTL bulk cultures
were harvested and viable lymphocytes were counted. Groups of
1.5 ´ 106 lymphocytes were resuspended in 200 ml of medium
containing 2 mg of biotinylated anti-CD3 Fab fragments. Control
groups did not receive biotinylated anti-CD3 Fab fragments. Cells
were left at 4°C for 25 min, washed to remove excess antibody and
aliquoted in 96-well plates in effector:target ratios ranging from
50:1 to 3:1 Following a 4-h incubation period, plates were spun,
radioactivity of harvested supernatant was counted using an auto-
matic gamma counter and percentage of killing was estimated
using the formula: %Cytotoxicity = [(experimental release – 
spontaneous release) / (maximum release – spontaneous release)]
´ 100.
RESULTS
MUC1 mucin targeting
Following transfection of the 410.4 mouse mammary cell line with
the human MUC1 mucin cDNA two of the resulting clones were
characterized and shown to express the MUC1 mucin. Specific
flow cytometric studies using the HMFG1 anti-MUC1 mucin
mAb, showed that 425CCR transfectant is a moderate MUC1
mucin expressor and the 413BCR transfectant a high expressor
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Figure 3 Cell binding studies of HMFG1 MAb by flow cytometry. Testing of HMFG1 mAb binding to (1) 413BCR; (2) 410.4; (3) MCF-7; (4) 425CCR cell
lines. Cells were labelled with HMFG1 (mouse mAb) and anti-mouse FITC-conjugated Ab. Dashed lines represent the negative control (PBS instead of first
layer mAb)clone (Figure 3). The HMFG1 showed stronger binding for the
413BCR cell line with 90–95% of the cells binding the mAb, while
in the case of 425CCR the percentage was 60–70%. Similar to the
413BCR cell line, 95% of MCF-7-positive control cells were
shown to bind the HMFG1 mAb. No antibody binding was
detected in the 410.4 parental cell line or the 435DNV vector
control cell line.
Direct streptavidinylation of HMFG1
Direct streptavidinylation of HMFG1 mAb was carried out using a
non-denaturing protocol (Figure 2). Initial sulphydryl group incor-
poration onto the HMFG1 mAb was carried out using SATA.
Reaction was carried out at different SATA:HMFG1 ratios, and
sulphydryl incorporation was calculated using the Ellman’s assay
and plotted (Figure 4). At SATA:HMFG1 ratio of 10:1 an incorpo-
ration of a mean 1.67 moles of -SH groups per mole of HMFG1
was found after deacetylation. Subsequently, a maleimide group
was introduced onto the streptavidin and finally thiolated HMFG1
and maleimide-conjugated SA were mixed in equimolar ratios
reacting to form an amide-thioether bond and thus streptavid-
inylated HMFG1 mAb. HMFG1 mAb streptavidinylated by this
approach was tested for both the ability to bind MUC1 mucin-
expressing cell lines and for carrying SA by flow cytometry
(Figure 5). The results clearly showed that streptavidinylated
HMFG1 can bind to the MUC1 mucin-expressing clone 413BCR,
but not to the non-MUC1 mucin-expressing parental 410.4 cell
line. Streptavidinylation of the HMFG1 mAb did not grossly affect
its immunoreactivity with the 413BCR cell line which was shown
to be similar to unconjugated HMFG1, with 95% of the cells
showing staining. Negative control experiments carried out with
the cross-linking reagents and second/third layer show no cross-
reactivity with the cell membrane.
Biotinylated anti-CD3 Fab fragments
Fab fragments of 1452C11 anti-CD3 mAb were generated by
papain digestion, meticulously purified by affinity chroma-
tography and confirmed by SDS-PAGE gel stained with
Coomassie brilliant blue (data not shown) and flow cytometry
(Figure 5). Flow cytometry showed 90–95% binding of purified
Fab fragments to CD3-positive T-cells. Biotinylation of Fab
fragments was carried out using NHS-iminobiotin at 7:1–50:1
biotin:Fab ratios. The mean number of biotin incorporation/Fab,
estimated by the HABA method, was found to range from 0.2 to 8
(data not shown). A biotin:Fab ratio of 30:1 was found to result in
a mean number of 3 moles of biotin incorporated per mole of Fab.
Cell binding studies by flow cytometry of T-cells labelled with
biotinylated anti-CD3 Fab fragments showed 90–99% positivity.
In addition, the same study showed that biotin conjugated to Fab
fragments retained the ability to cross-link SA.
Cross-linking of biotinylated anti-CD3 Fab fragments to
the streptavidinylated HMFG1 mAb
Flow cytometry
The ability of streptavidinylated HMFG1 to retain functional
biotin binding site and cross-link biotinylated anti-CD3 Fab frag-
ments was tested by flow cytometry (Figure 5). The results clearly
showed cross-linking of the two antibody constructs mediated 
by the SA–biotin bond in 90% of the cells (Figure 5). Negative
control experiments showed that no cross-reactivity occurred with
the cell membrane (Figure 5).
51Cr cytotoxicity assay
The biologic effect of the streptavidinylated HMFG1 mAbs and
biotinylated anti-CD3 Fab fragments was tested using a 51Cr cyto-
toxicity assay. Streptavidinylated HMFG1 mAb and biotinylated
anti-CD3 Fab fragments were separately incubated with target and
effector T-cells respectively to mimic the in vivo approach.
Biotinylated anti-CD3 Fab fragments were shown to successfully
redirect preactivated T-cells against target cells stained with strep-
tavidinylated HMFG1 mAb. Lysis was achieved at approximately
70% and 40% of the high (413BCR) and the low (425CCR)
MUC1 mucin expressing cell lines respectively, using an E:T ratio
of 50:1 (Figure 6). The control experiments consisting of non-
MUC1 mucin-expressing 410.4 parental cell line and unlabelled
MUC1 mucin-transfected cells or unlabelled T-cells did not
exhibit cytotoxic activity.
DISCUSSION
We have developed a novel antibody approach for tumour
immunotherapy consisting of biotinylated Fab fragments raised
against the CD3 region of effector T-cells and directly strepta-
vidinylated mAbs raised against the MUC1 mucin tumour antigen.
This is the first report describing the generation of the two anti-
body constructs for potential immunotherapeutic application and
showing that these constructs can specifically bind the cell
membrane, cross-link the CD3 receptor through a SA–biotin bond
and thereby induce tumour cell killing. This novel antibody
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Figure 4 Incorporation of -SH groups on HMFG1 mAb at different 
SATA:IgG molar ratios. The effect of the increasing concentration of SATA 
on the incorporation of reactive sulphydryl groups onto the HMFG1 mAb is
described. Increasing molar ratios of SATA to HMFG1, shown on the
abscissa, were allowed to react with 60 mM HMFG1. Sulphydryl incorporation
was measured using Ellmans reagentapproach might prove advantageous over previous antibody
approaches in in vivo applications as it is designed to separately
label tumour cells and T-cells and induce T-cell recruitment and
activation at the tumour site. A syngeneic solid tumour model
composed of a breast adenocarcinoma cell line transfected with
MUC1 mucin and preactivated T-cells was established to test
redirection of T-cell cytotoxicity using this novel indirect antibody
approach.
Streptavidinylation of HMFG1 mAb by sulphydryl-maleimide
coupling (maleimide groups bound to SA react with free -SH
groups on the HMFG1 antibody), resulted in a very stable amide-
thioether bond without altering the mAb and SA binding proper-
ties (Hashida et al, 1984). The introduction of -SH group onto
HMFG1 was achieved using SATA which offers several advan-
tages over other methodologies such as SAMSA and SPDP
(reviewed by (Duncan et al, 1983)). The most important advantage
is that SATA reacts under mild and non-denaturating conditions
with primary amines to form a covalently linked -SH group
‘protected’ from oxidation by an acetyl group. This can be ‘depro-
tected’ by hydroxylamine, which is specific for the thiol-carboxyl-
ate group, thus eliminating the potential presence of another thiol
that could quench or compete with subsequent sulphydryl reac-
tions. Our results showed 1.67 -SH groups incorporated per anti-
body and are in line with the results of other studies aiming at a
single substituent incorporation (Duncan et al, 1983; Jones &
Hudson, 1993). Duncan and colleagues found their results were in
agreement with the Poisson distribution, whereby 36% of the
derivatized antibody was monosubstituted, 31% bisubstituted and
24% unsubstituted.
Streptavidinylation and avidinylation of molecules has been
previously achieved indirectly by conjugating biotin onto the
target antibody which is then incubated with SA or avidin. The
major disadvantages of this conjugation reaction are: (a) loss of 
at least one binding site on the SA molecule engaged in the
SA–biotin bond and (b) addition of SA in the biotinylated anti-
body solution. In the latter case, dimeric and polymeric species
consisting of several antibody molecules bound together
(Hnatowich et al, 1987) may form and have to be removed prior to
administration to patients (Kalofonos et al, 1990). In our study, SA
was selected over avidin as it is unglycosylated and it had previ-
ously been suggested that glycans might interfere with cross-
linking and increase non-specific binding to tissues (Chaiet, 1964).
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Figure 5 Cell binding studies of the labelled Mab constructs by flow cytometry. 1: Testing of streptavidinylated HMFG1 mAb binding to 413BCR cell line. Cells
were stained with streptavidinylated HMFG1, rabbit anti-streptavidin Ab and FITC anti-rabbit Ab. 2: Testing of biotinylated 1452C11 Fab fragment binding to
T-cells. Cells were stained with biotinylated anti-CD3 Fab fragments and FITC-conjugated streptavidin; 95% positivity was reached. 3: Testing cross-linking of
biotinylated Fab fragment to streptavidinylated HMFG1 mAb. T-cells were labelled with biotinylated Fab fragments, streptavidinylated HMFG1, rabbit
anti-streptavidin Ab and anti-rabbit FITC-conjugated Ab. 4: A representative negative control experiment included T-cells labelled with biotinylated irrelevant Fab
fragments, rabbit anti-streptavidin Ab and anti-rabbit FITC-conjugated Ab. Dashed lines represent the negative control (PBS instead of first layer mAb)
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0In a review of the current literature only a single study could be
found reporting direct IgG conjugation to SA by chemical methods
for immunoscintigraphy purposes (Sheldon, 1992). In another
study, direct conjugation of SA to a single-chain antibody frag-
ment (Dubel, 1995) was achieved by DNA recombinant methods.
The major disadvantage of the later approach is that laborious
purification procedures of scFv-SA from bacteria lysates are
required since the amount of scFv recovered per litre of bacterial
culture supernatant is very low (100–500 mg) (George et al, 1994).
The current study also reports the refinement of procedures for
the chemical generation of biotinylated anti-CD3 Fab fragments.
The biotin:Fab ratio of 30:1 was selected as at this ratio the mean
number of biotin moles incorporated per Fab is three (the majority
of Fab fragments have incorporated 2–4 biotin molecules) while
antigen-binding specificity is retained. Furthermore, a previous
study carried out on NHS-esters, similar to the biotin ester used in
our study, reported hydrolysis reactions to occur (Anjaneyula et al,
1987) making a higher of 1 biotin:Fab ratio desirable. Reports on
biotinylation of Fab fragments are present in the literature,
including a recent study by Otsuji describing the biotinylation of
genetically engineered Fab fragments, using NHS biotin (Otsuji,
1996) and a report by Weiss describing the complete generation of
biotinylated Fab fragments by recombinant methods (Weiss,
1994).
Control cell binding studies showed that the conditions used in
the coupling reactions of both the biotinylation of Fab fragments
and of the HMFG1 streptavidinylation did not affect the
immunoreactivity of the conjugates nor the ability of SA to bind
biotin.
In our in vitro studies, MUC1 mucin-positive tumour cells
labelled with streptavidinylated HMFG1 provided a matrix for
multimeric binding of the biotinylated Fab fragments and facili-
tated CD3 cross-linking on preactivated T-cells resulting in tumour
cell killing. Up to date the use of preactivated T-cells in a BiAb
setting remains controversial. Current opinion indicates that Ab-
mediated cross-linking of the CD3 complex is not in itself suffi-
cient to activate resting T-cells. Many studies have shown that
primed or preactivated T-cell use is a prerequisite for successful
BiAb application (e.g. Weiner, 1994). Methods of in vivo and ex-
vivo T-cell activation have been developed using mainly cytokines
such as IL-2 and mitogens such as ConA and staphylococcal
enterotoxin-B (Weiner et al, 1994). Although the signalling path-
ways by which IL-2 mediates its effect are not fully understood it
is well-established in vitro that IL-2 is a potent T-cell mitogen. A
recently developed clonogenic assay showed the importance of
repeated administration of BiAbs and IL-2 for tumour killing
(Haagen et al, 1995). Redirection of T-cells was shown to occur in
the presence of cells expressing MUC1 mucin (413BCR and
425CCR) that could engage the streptavidinylated HMFG1 arm
but not in the presence of cells not expressing the target antigen
(410.4). Induction of tumour cell lysis was strictly dependent upon
the expression of the MUC1 mucin molecule on target cells as
demonstrated by the different susceptibility to lysis of differen-
tially expressing MUC1 mucin-transfected cells and the negative
parental cell line.
The results of the in vitro cytotoxicity assays testing the novel
SA–biotin indirect antibody approach are in agreement with other
studies testing redirection of T-cells against tumour cells with
BiAb and previous indirect methods (Perez et al, 1985; George et
al, 1994).
The mechanisms through which antibody redirected T-cells
exert their cytotoxic effect over antigen expressing tumour cells
have not been fully defined. A recent study showed that anti-
CD3 redirection of T-cells induced killing of BCL1 expressing
lymphoma via the FAS pathway suggesting the process is
mediated by apoptosis (Armstrong & Vitetta, 1996). Interestingly,
another in vitro study carried out by Gimmi and colleagues, inves-
tigating the paucity of clinical responses in patients with immune
responses to MUC1 mucin expressing malignancies, showed that
MUC1 mucin was responsible for inducing apoptosis of activated
T-cells (Gimmi, 1996). Using our antibody mediated T-cell
redirecting approach such a tumour escape mechanism could be
overridden. Our theory is supported by the findings of Katayose et
al (1996) who showed T-cell redirection against MUC1 mucin
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Figure 6 51Cr cytotoxicity assay. 51Cr labelled 413BCR, 425CCR and 410.4 tumour cell lines were incubated with/without streptavidinylated HMFG1 mAb.
T-cells were incubated with/without biotinylated anti-CD3 Fab fragments. T-cells and tumour cells were incubated at different effector:target ratios and allowed to
react. Data shown are representative of three independent experiments. Bars indicate standard error. At all E:T ratios the percentage lysis of MUC1 expressors
in the presence of both antibody constructs differs significantly from the controls. (A) (u) 413BCR cells stained with streptavidinylated HMFG1 were incubated
with T-cells stained with biotinylated 1452C11 Fab fragments; (u u) unstained 413BCR cells were incubated with stained T-cells; (Ñ) stained 413BCR cells were
incubated with unstained T-cells. (B) (u) 425CCR cells stained with streptavidinylated HMFG1 were incubated with T-cells stained with biotinylated 1452C11
Fab fragments; (u u) unstained 425CCR cells were incubated with stained T-cells; (Ñ) 410.4 parental cell line pre-incubated with streptavidinylated HMFG1 in
the presence of biotinylated 1452C11 Fab fragment-labelled T-cellsexpressing cells by anti-CD3 ´ anti-MUC1 mucin BiAb results in
tumour cell lysis.
When compared to BiAb methodologies our SA–biotin indirect
approach has similar advantages to the indirect approaches
developed by Gilliland et al (1988) and George et al (1994).
Specifically, it has the advantage of being less expensive, since the
biotinylated anti-CD3 Fab fragments can be used as a ‘universal
arm’ to redirect effector cells against a variety of tumours, and
furthermore offers the opportunity of targeting more than one
tumour associated antigen at the same time. When compared to the
previous indirect antibody approaches (Gilliland et al, 1988;
George et al, 1994), the use of streptavidinylated anti-tumour anti-
bodies and biotinylated anti-CD3 Fab fragments for effector cell
recruitment could provide, at least theoretically, two additional
advantages. First, the SA–biotin bonding is based on a stronger
interaction than antibody–antibody. Specifically, while the associ-
ation constant (Ka) of the antibodies for their antigen varies from
105–1012 M–1 (Morris, 1995) the SA–biotin bonding is one of the
strongest non-covalent interactions with Ka = 1015 M–1 (Green,
1975). Such strong Ka may be an advantage in an in vivo model
where there is a rapid turnover of tumour-infiltrating lymphocytes.
Secondly, each SA molecule can bind four molecules of biotin
(Argarana, 1986). As a result, in an in vivo model a streptavidinyl-
ated mAb to biotinylated Fab ratio of four could theoretically be
translated to an improved effector to tumour cell ratio. Therefore,
sequential administration of streptavidinylated mAb followed by
T-cells labelled with biotinylated anti-CD3 (provided that high
tumour:background ratio is achieved), should ensure that most
tumour cells would be coated with streptavidinylated Fab frag-
ments and that T-cells would only be activated by the SA at the
surface of the target cells and not by residual unbound strepta-
vidinylated mAb.
More importantly it is possible that conventional BiAb might
diffuse directly into the interstitial space of the tumour. However,
it seems more likely that the BiAb would first bind to the effector
cell, extravasate and then be carried into the tumour tissue. As a
result, smaller antibody constructs would have the advantage over
conventional BiAbs in penetrance of solid tumours. Every
biotinylated Fab fragment labelled CTL that has entered the
tumour tissue could become cross-linked on the streptavidinylated
mAb bound on tumour cells and react against the tumour cells,
regardless of its specificity. Furthermore, antigen specificity of
labelled CTL would be blocked by the anti-CD3 Fab monomers
resulting only in activation of the cell at the tumour site where
biotinylated Fab fragments become cross-linked (Perez et al,
1985) without inappropriate cross-linking occurring elsewhere.
In summary, we developed a novel indirect antibody approach
for immunotherapy of solid tumours based on the separate
labelling of tumour cells (MUC1 mucin) and T-cells (CD3
epitope) with antibodies chemically conjugated to biotin and strep-
tavidin moieties that bring them into proximity resulting in tumour
cell death. Our future studies aim to investigate whether the sepa-
rate (thus ex-vivo) labelling of T-cells with biotinylated Fab frag-
ments and tumour cells with streptavidinylated HMFG1 will result
in T-cell recruitment at the tumour site and CTL-mediated lysis 
of MUC1 mucin-transfected BALB/c tumour cell lines in a
syngeneic mouse model. If successful, this approach could open
new avenues for selective destruction of human tumours by
activated T-cells avoiding the complications associated with the
currently available treatments.
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